version: 2

sources:
  - name: orange_book
    description: >
      The publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) 
      identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) 
      under the Federal Food, Drug, and Cosmetic Act (the Act) and related patent and exclusivity information. 
      For more information on the Orange Book including its history, see the Orange Book Preface.
    schema: sagerx_lake
    tables:
      - name: orange_book_exlusivity
        description: Related exclusivity information of  drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).
        columns:
          - name: appl_type
            description: The type of new drug application approval. New Drug Applications (NDA or innovator) are 'N'. Abbreviated New Drug Applications (ANDA or generic) are 'A'.
          - name: appl_no
            description: The FDA assigned New Drug Application (NDA) number to the application. Format is nnnnnn.
          - name: product_no
            description: The FDA assigned number to identify the application products. Each strength is a separate product. May repeat for multiple part products. Format is nnn.
          - name: exclusivity_code
            description: Code to designate exclusivity granted by the FDA to a drug product. Format is nnnnnnnnnn.
          - name: exclusivity_date
            description: The date the exclusivity expires. Format is MMM DD, YYYY.

      - name: orange_book_patent
        description: Related patent information of drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).
        columns:
          - name: appl_type
            description: The type of new drug application approval.  New Drug Applications (NDA or innovator) are 'N'.  Abbreviated New Drug Applications (ANDA or generic) are 'A'.
          - name: appl_no
            description: The FDA assigned number to the New Drug Application (NDA). Format is nnnnnn.
          - name: product_no
            description: The FDA assigned number to identify the application products. Each strength is a separate product. May repeat for multiple part products. Format is nnn.
          - name: patent_no
            description: Patent numbers as submitted by the applicant holder for patents covered by the statutory provisions. May repeat for multiple applications and multiple products. Includes pediatric exclusivity granted by the agency. Format is nnnnnnnnnnn.
          - name: patent_expire_date_text
            description: The date the patent expires as submitted by the applicant holder including applicable extensions. The format is MMM DD, YYYY.
          - name: drug_substance_flag
            description: Patents submitted on FDA Form 3542 and listed after August 18, 2003 may have a drug substance flag indicating the sponsor submitted the patent as claiming the drug substance. Format is Y or null.
          - name: drug_product_flag
            description: Patents submitted on FDA Form 3542 and listed after August 18, 2003 may have a drug product flag indicating the sponsor submitted the patent as claiming the drug product. Format is Y or null.
          - name: patent_use_code
            description: Code to designate a use patent that covers the approved indication or use of a drug product.  May repeat for multiple applications, multiple products and multiple patents. Format is nnnnnnnnnn.
          - name: delist_flag
            description: >
              Sponsor has requested patent be delisted. 
              This patent has remained listed because, under Section 505(j)(5)(D)(i) of the Act, a first applicant may retain eligibility for 180-day exclusivity based on a paragraph IV certification to this patent for a certain period.
              Applicants under Section 505(b)(2) are not required to certify to patents where this flag is set to Y. 
              Format is Y or null.
          - name: submission_date
            description: The date on which the FDA receives patent information from the new drug application (NDA) holder. Format is Mmm d, yyyy.

      - name: orange_book_products
        description: Drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).
        columns:
          - name: ingredient
            description: The active ingredient(s) for the product. Multiple ingredients are in alphabetical order, separated by a semicolon.
          - name: df_route
            description: The product dosage form and route separated by a semi-colon. The format is not all uppercase.
          - name: trade_name
            description: The trade name of the product as shown on the labeling.
          - name: applicant
            description: The firm name holding legal responsibility for the new drug application. The firm name is condensed to a maximum twenty character unique string.
          - name: strength
            description: The potency of the active ingredient. May repeat for multiple part products.
          - name: appl_type
            description: The type of new drug application approval. New Drug Applications (NDA or innovator) are ”N”. Abbreviated New Drug Applications (ANDA or generic) are “A”.
          - name: appl_no
            description: The FDA assigned number to the application. Format is nnnnnn.
          - name: product_no
            description: The FDA assigned number to identify the application products. Each strength is a separate product. May repeat for multiple part products. Format is nnn.
          - name: te_code
            description: The Therapeutic Equivalence (TE) Code indicates the therapeutic equivalence rating of generic to innovator Rx products.
          - name: approval_date
            description: >
              The date the product was approved as stated in the FDA approval letter to the applicant.  
              The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: 'Approved prior to Jan 1, 1982'.
          - name: rld
            description: The Reference Listed Drug (RLD) is a drug product approved under section 505(c) of the FD&C Act for which FDA has made a finding of safety and effectiveness. In the electronic Orange Book, an RLD is identified by 'RLD' in the RLD column.
          - name: rs
            description: A 'reference standard' is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an in vivo bioequivalence study required for approval of an ANDA. In the electronic Orange Book, a reference standard is identified by 'RS' in the RS column.
          - name: type
            description: The group or category of approved drugs. Format is RX, OTC, DISCN.
          - name: applicant_full_name
            description: The full name of the firm holding legal responsibility for the new drug application.
